Workflow
ZACKS
icon
Search documents
CRC-BRY Merger Tops the Weekly Oil & Gas Stock Roundup Story
ZACKS· 2025-09-24 18:16
Core Insights - Oil prices remained stable while natural gas prices experienced a decline, influenced by various market dynamics and corporate activities in the energy sector [1][2][3] Mergers and Acquisitions - California Resources Corporation (CRC) announced a merger with Berry Corporation (BRY) in an all-stock deal valued at approximately $717 million, which includes Berry's net debt. This merger aims to unlock operational synergies, reduce costs, and enhance cash flow generation [4][5] - Following the merger, CRC shareholders will own about 94% of the combined entity, which will strengthen CRC's asset portfolio by adding high-quality, conventional oil-weighted production assets [5][6] - Chord Energy is set to acquire Williston Basin assets from Exxon Mobil's subsidiary, XTO Energy, for $550 million. This acquisition will enhance Chord's presence in the Williston Basin and is expected to contribute 9,000 barrels of oil equivalent per day to its production [6][7][8] Regulatory Developments - Pembina Pipeline secured approval from the Canada Energy Regulator for a negotiated settlement regarding the Alliance Pipeline, which is crucial for the natural gas transmission system between Canada and the U.S. This approval is expected to ensure smooth operations for the pipeline over the next decade [9][10][11] Environmental Initiatives - Petrobras has approved the construction of Brazil's first Carbon Capture and Storage (CCS) pilot project, aiming to capture and store up to 100,000 tons of CO2 annually. This project is part of Brazil's commitment to carbon neutrality by 2050 and will leverage Petrobras' expertise in offshore technologies [11][12][13] Market Performance - The Energy Select Sector SPDR saw a slight decline of 0.1% last week, with mixed stock performances among major oil and gas companies. Over the past six months, the sector fund has decreased by approximately 4% [14][15]
Can Rigetti's Recent Grants Accelerate Its Quantum Computing Roadmap?
ZACKS· 2025-09-24 18:11
Key Takeaways Rigetti won $5.8M AFRL contract, $5.48M AFOSR award and a 3.5M pound Innovate UK grant in 2025.AFRL funds quantum networking, AFOSR targets qubit defects and Innovate UK drives error correction.RGTI shares jumped 10.9% on AFRL news and are up 106.1% year to date, outpacing industry gains.Rigetti Computing (RGTI) has secured a series of significant grants over the past six months, underscoring both government confidence and the commercial relevance of its quantum roadmap. Most recently, in Sept ...
Down 33.4% YTD, Can Select Medical Stitch Back its Growth Story?
ZACKS· 2025-09-24 18:06
Key Takeaways Select Medical shares are down 33.4% in 2025, far underperforming the industry and S&P 500.Critical Illness Recovery Hospitals face falling admissions, patient days and operating income.Rehabilitation Hospitals show growth with higher admissions and strong margins.Select Medical Holdings Corporation (SEM) has had a brutal run so far in 2025. Shares have plunged 33.4% year to date, sharply lagging the industry’s 29.7% gain and the S&P 500’s 14.2% growth. Currently trading at $12.55, the stock s ...
ADM Collaborates With Alltech to Enrich Customers' Experience
ZACKS· 2025-09-24 18:01
Key Takeaways ADM, in collaboration with Alltech, will roll out a North American animal feed joint venture.The venture will align the companies' complementary feed strengths in North America.The companies will offer products and solutions for livestock, equine and more.Archer Daniels Midland Company (ADM) is focused on optimizing the organizational and operational structure across Human and Animal Nutrition. In the latest development, the company, in collaboration with Alltech, has agreed to roll out a Nort ...
Morgan Stanley, Zerohash to Launch Crypto Trading for ETrade Clients
ZACKS· 2025-09-24 17:50
Core Insights - Morgan Stanley has partnered with Zerohash to allow E*TRADE clients to trade popular cryptocurrencies starting in the first half of 2026 [1][7] - Initial offerings will include Bitcoin, Ethereum, and Solana, with plans for a comprehensive wallet solution in the future [2][7] - The firm is developing an asset-allocation strategy for cryptocurrencies, with portfolio weights varying based on client objectives [3] Company Strategy - Morgan Stanley aims to integrate digitized assets, traditional assets, and cryptocurrencies into a unified ecosystem for clients [4] - The initiative is expected to enhance revenue through trading spreads, advisory fees, and future services like custody and tokenization [4][7] - The firm recognizes the opportunity to simplify the user experience for clients navigating the traditional finance and decentralized finance divide [4] Competitive Landscape - Competitors like Robinhood and Charles Schwab are also expanding their cryptocurrency offerings, with Robinhood generating significant revenue from its crypto business [5] - Schwab plans to introduce spot cryptocurrency trading by next year, indicating a competitive environment for Morgan Stanley [5] Performance Metrics - Over the past six months, Morgan Stanley's shares have increased by 28.4%, outperforming the industry growth of 26.1% [6]
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
ZACKS· 2025-09-24 17:46
Key Takeaways Biogen got an FDA CRL for its sNDA seeking approval of a higher-dose regimen of Spinraza.The FDA requested CMC updates, with no deficiencies flagged in clinical data for the higher dose.EMA and other regulators are reviewing filings, and Japan has already approved the higher dose.Biogen (BIIB) announced that the FDA has issued a complete response letter (CRL) to its supplemental new drug application (sNDA) seeking label expansion for a higher dose of its renowned spinal muscular atrophy (SMA) ...
3 Reasons Growth Investors Will Love United Fire (UFCS)
ZACKS· 2025-09-24 17:46
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...
SYM vs. DUOL: Which Technology Services Stock Has an Edge Right Now?
ZACKS· 2025-09-24 17:40
Key Takeaways Symbotic posted $22.4B backlog and expects $590-$610M in Q4 revenues with EBITDA of $45-$49M.DUOL boosted 2025 outlook as AI cut costs, lifting gross margin to 72.4% and driving 148 new courses.DUOL's paid subscribers rose 37% in Q2, revenues increased 41% and earnings beat estimates by 65.4%.Symbotic (SYM) and Duolingo (DUOL) are well-established names in the Zacks Technology Services industry. Symbotic, based in Wilmington, MA, develops, commercializes, and deploys innovative, comprehensive ...
HOOD Launches "Asset Match" Through TradePMR: A Win for RIA Clients?
ZACKS· 2025-09-24 17:31
Key Takeaways RIAs can offer investors a 0.50% cash bonus on TradePMR deposits from October 2025 to March 2026.Asset Match supports HOOD's AUM growth and revenues through product diversification.HOOD continues to expand its offerings with copy trading, prediction markets and community features.TradePMR, a subsidiary of Robinhood Markets, Inc. (HOOD) , has introduced the “Asset Match” feature for independent registered investment advisers (RIAs). This will enable independent RIAs to offer investors a small c ...
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
ZACKS· 2025-09-24 17:25
Key Takeaways Lilly's Mounjaro and Zepbound now drive about half of its total revenues.Novo Nordisk cut 2025 guidance as Wegovy and Ozempic face supply and pricing pressures.LLY forecasts $60B-$62B revenues in 2025, up over 30% year over year.Novo Nordisk (NVO) and Eli Lilly (LLY) dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products.  Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide, as Mounjaro for type II diabetes and as Zepbound for obes ...